Drugs / AKK-WST01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04797442 | Jul 2021 → Nov 2022 | obesity disorder, type 2 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AKK-WST01 | “AKK-WST01 supplementation showed high colonization efficiency and significant reductions in body weight, fat mass, and HbA1c” PMID 39879980 ↗ Jan 2025 |
| Modality | Other / unclassified | “supporting the potential for gut microbiota-guided probiotic supplementation” PMID 39879980 ↗ Jan 2025 |
| Route | Oral | “orally given WST01 strain product” NCT04797442 ↗ |